FY2025 Earnings Estimate for Amgen Issued By Zacks Research

Amgen Inc. (NASDAQ:AMGN) – Analysts at Zacks Research lifted their FY2025 EPS estimates for Amgen in a note issued to investors on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the medical research company will earn $21.20 per share for the year, up from their prior estimate of $20.80. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q4 2025 earnings at $4.64 EPS and Q2 2026 earnings at $5.34 EPS.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.

Other research analysts have also issued research reports about the stock. Raymond James Financial started coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Truist Financial initiated coverage on shares of Amgen in a report on Monday. They issued a “hold” rating and a $318.00 price objective on the stock. HSBC lifted their target price on shares of Amgen from $343.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. DZ Bank upped their price target on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, UBS Group lowered their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $333.74.

Amgen Stock Performance

Shares of Amgen stock opened at $344.57 on Thursday. The firm has a market cap of $185.54 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen has a 52 week low of $253.30 and a 52 week high of $345.84. The business’s fifty day simple moving average is $306.32 and its 200-day simple moving average is $294.25.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio is currently 73.57%.

Insider Activity

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock worth $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

A number of large investors have recently made changes to their positions in AMGN. Wealth Preservation Advisors LLC acquired a new position in shares of Amgen during the first quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 2nd quarter worth about $27,000. CBIZ Investment Advisory Services LLC increased its holdings in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares during the last quarter. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the 2nd quarter valued at about $32,000. Finally, Howard Hughes Medical Institute acquired a new stake in shares of Amgen during the 2nd quarter worth about $32,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.